Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Growth Performance Trended Historically, And What Lies Ahead?
The market size for weight loss drugs, specifically glucagon-like peptide (glp)-1 agonists, has witnessed speedy expansion in recent years. The market is expected to escalate from a value of $13.38 billion in 2024 to $15.5 billion in 2025, reflecting a compound annual growth rate (CAGR) of 15.9%. The historical growth of this market can be credited to several factors such as heightened frequency of obesity, an upsurge in type 2 diabetes cases, increased awareness of health risks associated with obesity, amplified healthcare spending, a greater emphasis on managing chronic diseases, and improved access to healthcare services.
The market size for glucagon-like peptide (GLP)-1 agonists, a class of weight loss drugs, is predicted to undergo substantial growth in the coming years, expanding to $28.3 billion in 2029 at a CAGR of 16.3%. Factors influencing this projected growth during the forecast period include heightened demand for effective weight reduction options, broader use of drugs beyond diabetes applications, increased funding in R&D, growing prevalence of personalized medicine, and better public awareness via direct-to-consumer advertising. Notable trends anticipated during this period are the creation of oral GLP-1 formulations, progress in persistent-release drug delivery, the incorporation of digital health tools for tracking, the application of artificial intelligence in drug research and creation, and advancements in peptide engineering to boost efficacy.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24226&type=smp
What are the Fundamental Drivers and Innovations Shaping the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
The escalating incidence of obesity is anticipated to fuel the expansion of the market for glucagon-like peptide (GLP)-1 agonist weight loss drugs. Obesity, a health hazard, is identified by the excessive accumulation of body fat. The surge in obesity rates can be attributed to unhealthy dietary patterns which involve high consumption of fast food and sugar-laden beverages, devoid of proper nutrition and balance. The increasing number of individuals grappling with obesity and its associated health issues fuels the demand for effective treatment options. This, in turn, spurs the use of glucagon-like peptide (GLP)-1 agonist weight loss drugs owing to their demonstrated capability to facilitate weight loss and promote metabolic health. For instance, the World Health Organization, an intergovernmental organization based in Switzerland, reported in March 2024 that one in eight people worldwide were dealing with obesity in 2022. Out of the 2.5 billion adults suffering from overweight, nearly 890 million were identified as obese. Additionally, about 43% of the worldwide adult population was overweight, with 16% being categorized as obese. Hence, the escalating incidence of obesity is propelling the expansion of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market.
How Is the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Segmented?
The glucagon-like peptide (glp)-1 agonists weight loss drugsmarket covered in this report is segmented –
1) By Drugs: Semaglutide; Liraglutide; Tirzepatide; Other Drugs
2) By Route of Administration: Parenteral; Oral
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Pharmacies
Subsegments:
1) By Semaglutide: Ozempic; Wegovy; Rybelsus
2) By Liraglutide: Saxenda; Victoza
3) By Tirzepatide: Mounjaro; Zepbound
4) By Other Drugs: Exenatide; Dulaglutide; Albiglutide; Efpeglenatide
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24226&type=smp
Which Regions Are Driving the Next Phase of the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Growth?
North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2024. The regions covered in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
Leading corporations in the glucagon-like peptide (GLP)-1 agonist weight loss drug sector are pioneering new obesity treatment methods for improving effectiveness and boosting patient outcomes. These treatments involve therapies that copy the GLP-1 hormone to control appetite, heighten the feeling of fullness, and encourage weight loss. They aid in obesity management by refining metabolic function and enabling continual weight control. For example, Eli Lilly and Company, a pharmaceutical firm based in the US, obtained approval from the US Food and Drug Administration for Zepbound, a chronic weight management medicine for adults suffering from obesity or overweight along with associated health issues like type 2 diabetes or sleep apnea, in November 2023. The drug functions by stimulating GIP and GLP-1 hormone receptors to curb appetite and bolster metabolic function.
View the full report here:
How Is the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Defined and What Are Its Core Parameters?
Glucagon-like peptide (GLP)-1 agonists are medications that replicate the action of the GLP-1 hormone to help control blood sugar and reduce appetite. They boost insulin release, delay stomach emptying, and increase feelings of fullness. Initially designed for type 2 diabetes, they are now commonly used for weight management in overweight and obese patients.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24226
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model